AKT1 and cancer: For example, the combined use of ICIs with targeted therapies that inhibit specific oncogenic pathways, such as the PI3K/AKT/mTOR pathway, could enhance the therapeutic effect by simultaneously targeting the immune system and cancer cells (44).